Also, comparing the expression and functional differences of IL-33/ST2 between different types or severity of AMD will not only help us better understand the complex mechanism of the disease but also provide new clues about the immunotherapeutic treatment paradigm. This evidence concerns the gene IL33 and age-related macular degeneration.